Tarsus Pharmaceuticals, Inc. (TARS)
NASDAQ: TARS · Real-Time Price · USD
70.03
+1.83 (2.68%)
Oct 26, 2026, 4:00 PM EDT - Market closed
Tarsus Pharmaceuticals Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 606.33 | 451.36 | 182.95 | 17.45 | 25.82 | 57.03 | |
Revenue Growth | 105.17% | 146.71% | 948.62% | -32.42% | -54.73% | - |
Cost of Revenue | 105.07 | 95.01 | 66.21 | 51.91 | 43.58 | 43.79 |
Gross Profit | 501.26 | 356.35 | 116.74 | -34.46 | -17.76 | 13.24 |
Selling, General & Admin | 526.44 | 427.32 | 237.31 | 108.7 | 44.95 | 25.4 |
Research & Development | 23.36 | - | - | - | - | - |
Operating Expenses | 549.8 | 427.32 | 237.31 | 108.7 | 44.95 | 25.4 |
Operating Income | -48.54 | -70.97 | -120.57 | -143.16 | -62.71 | -12.16 |
Interest Expense | -8.77 | -8.94 | -7.85 | -3.35 | -2.2 | - |
Interest & Investment Income | 15.48 | 15.75 | 15.01 | 10.34 | 3.5 | 0.04 |
Other Non Operating Income (Expenses) | -0.34 | -0.2 | 0.39 | 0.02 | 0.09 | -0 |
EBT Excluding Unusual Items | -42.16 | -64.36 | -113.02 | -136.15 | -61.33 | -12.12 |
Gain (Loss) on Sale of Investments | 2.81 | - | -0.59 | 0.26 | -0.77 | -1.58 |
Gain (Loss) on Sale of Assets | - | - | - | - | - | -0.07 |
Other Unusual Items | - | - | -1.94 | - | - | - |
Pretax Income | -39.35 | -64.36 | -115.55 | -135.89 | -62.1 | -13.77 |
Income Tax Expense | 7.13 | 2.06 | - | - | -0 | 0.06 |
Net Income | -46.48 | -66.42 | -115.55 | -135.89 | -62.09 | -13.83 |
Net Income to Common | -46.48 | -66.42 | -115.55 | -135.89 | -62.09 | -13.83 |
Net Income Growth | - | - | - | - | - | - |
Shares Outstanding (Basic) | 43 | 42 | 38 | 29 | 25 | 21 |
Shares Outstanding (Diluted) | 43 | 42 | 38 | 29 | 25 | 21 |
Shares Change | 7.95% | 11.11% | 27.98% | 19.35% | 19.78% | 231.12% |
EPS (Basic) | -1.08 | -1.59 | -3.07 | -4.62 | -2.52 | -0.67 |
EPS (Diluted) | -1.08 | -1.59 | -3.07 | -4.62 | -2.52 | -0.67 |
EPS Growth | - | - | - | - | - | - |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Free Cash Flow | 56 | -22.31 | -84.59 | -119 | -49.54 | 3.16 |
Free Cash Flow Per Share | 1.30 | -0.53 | -2.25 | -4.05 | -2.01 | 0.15 |
Gross Margin | 82.67% | 78.95% | 63.81% | -197.50% | -68.81% | 23.22% |
Operating Margin | -8.00% | -15.72% | -65.90% | -820.53% | -242.92% | -21.32% |
Profit Margin | -7.66% | -14.71% | -63.16% | -778.89% | -240.51% | -24.25% |
Free Cash Flow Margin | 9.24% | -4.94% | -46.24% | -682.04% | -191.88% | 5.54% |
EBITDA | -46.2 | -69.15 | -119.34 | -142.28 | -62.39 | -11.85 |
EBITDA Margin | -7.62% | -15.32% | -65.23% | - | -241.66% | -20.77% |
D&A For EBITDA | 2.34 | 1.82 | 1.23 | 0.88 | 0.33 | 0.31 |
EBIT | -48.54 | -70.97 | -120.57 | -143.16 | -62.71 | -12.16 |
EBIT Margin | -8.00% | -15.72% | -65.90% | - | -242.92% | -21.32% |
Revenue as Reported | 606.33 | 451.36 | 182.95 | 17.45 | 25.82 | 57.03 |